The DKSH distribution of Roche Accu-Chek Guide test strips - quiet backbone for diabetes care
01.07.2026 - 09:22:53 | ad-hoc-news.de
By Nora Whitfield, ad hoc news Accessories & Components Desk. Reviewed July 01, 2026, 3:22 AM ET. Details in the imprint.
DKSH’s distribution of Roche Accu-Chek Guide blood glucose test strips is easy to miss until you watch someone line up a strip with a tiny drop of blood on a kitchen table at 6 a.m. The foil packet crinkles, the meter beeps, and the strip quietly does its job.
What DKSH actually does
DKSH is not the manufacturer of Accu-Chek Guide test strips, but in many Asian markets it is the behind-the-scenes distributor that gets those small foil boxes into hospital pharmacies and neighborhood drugstores. Under long-running partnerships with Roche, DKSH handles logistics, marketing services, and regulatory support for the Accu-Chek diabetes portfolio across parts of Southeast Asia.
On Roche’s own Accu-Chek Guide product page, the test strips are presented as part of a system designed for “spill-resistant” dosing and simple, everyday blood glucose checks. DKSH’s role is to move that everyday essential from Roche’s factories into the hands of patients who test once or several times a day, often for years. The consumable nature of strips means every box that reaches a shelf is part of a recurring revenue stream for both Roche and DKSH’s Healthcare segment.
Accessory product with recurring demand
Accu-Chek Guide test strips are a textbook accessory product: they only work with compatible Accu-Chek Guide meters, and patients need a steady supply to use the device at all. A typical patient may use 2 to 4 strips per day, more if they are managing insulin closely. That turns a $20 to $40 box of strips into a monthly staple, not a once-a-year gadget. In DKSH markets like Thailand, Vietnam, and Malaysia, Roche relies on DKSH’s established healthcare distribution network to make sure those boxes are consistently available.
Standing in a Bangkok clinic pharmacy, you’ll see the Accu-Chek logo lined up in glass cabinets among other diabetes supplies, but the DKSH name is nowhere on the packaging. The tie-in appears instead in Roche and DKSH’s partnership announcements and DKSH’s Healthcare segment presentations, where executives such as DKSH Healthcare Co-Head Bijay Singh emphasize long-term collaborations with global pharma and medtech players. For investors, that invisible presence is exactly the point: DKSH captures service revenue without carrying the brand risk of the end product.
DKSH Healthcare and Roche partnership
Explore how DKSH’s Healthcare segment supports global pharma and medtech brands such as Roche in Asia and what that means for recurring accessory products like Accu-Chek Guide test strips.
US angle and global footprint
In the US, Accu-Chek Guide test strips are sold directly by Roche’s US business and major retailers, so DKSH does not sit between the manufacturer and the consumer in the same way. US investors, however, can still view this accessory line as a proxy for how DKSH’s healthcare distribution model scales: diabetes is growing worldwide, and test strips are among the more defensible recurring items in that ecosystem.
Roche’s diabetes care portfolio, including Accu-Chek Guide, is available in over 100 countries. DKSH’s own materials highlight that its Healthcare business covers more than a dozen Asian markets, offering services from regulatory affairs to warehousing and last-mile distribution for prescription drugs, devices, and diagnostics. That puts DKSH in the middle of long-running demand trends like aging populations, lifestyle-related diabetes, and the shift toward home monitoring. Accessory products such as test strips represent repeat orders rather than one-off device installations, supporting steadier volume through DKSH’s depots.
How the strips work day to day
Accu-Chek Guide strips are designed for capillary blood from a fingertip. A patient pricks the skin, touches the edge of the strip to the blood drop, and the meter reads the glucose concentration within seconds. Roche stresses features like a larger dosing area and a design that reduces wasted strips from misdosing. The meters and strips are subject to regulatory oversight, including clearance or approval by agencies such as the FDA in the US and equivalent bodies in Asian markets.
DKSH’s responsibility starts earlier, at import paperwork and compliance with storage requirements. Test strips are sensitive to humidity, temperature, and shelf life. Logistics teams at DKSH need to keep warehouses within specified climate ranges and ensure first-expire-first-out rotation. A delayed shipment or a mismanaged warehouse can turn into expired stock, which is unsellable and potentially unsafe. That operational discipline is where DKSH earns its margins as a distribution specialist.
Contract structure and economics
While specific contract terms between DKSH and Roche are not public, DKSH generally operates on a service-fee model plus margin-based elements in its Healthcare distribution agreements. The company provides field marketing, sales force support, and medical detailing in addition to logistics. For accessory products like Accu-Chek strips, this can translate into frequent orders from pharmacies and clinics, giving DKSH regular volume even if individual prices are relatively low.
In its annual and half-year reports, DKSH breaks out the Healthcare segment, which includes distribution of prescription drugs, over-the-counter remedies, medical devices, and diagnostic products. Revenue tends to be driven by a mix of high-value pharmaceuticals and high-volume consumables. A box of test strips may not move the needle on its own, but across thousands of outlets and repeated prescriptions, the contribution can be meaningful. Investors following DKSH stock should watch Healthcare segment growth and margin trends as a proxy for how well these accessory lines are performing.
Supply chain resilience and COVID lessons
DKSH, like other healthcare distributors, had to navigate pandemic-era disruptions. Border closures, flight cancellations, and sudden demand spikes made it harder to keep even basic diabetes supplies flowing smoothly. Post-pandemic, both DKSH and its partners have put more emphasis on diversified logistics routes, local inventory buffers, and digital tools for demand forecasting.
For an accessory product such as Accu-Chek Guide strips, resilience matters less in terms of one-off surges and more in terms of preventing stockouts. A pharmacy that runs out of strips forces patients to hunt for alternatives or change meters, which can erode brand loyalty and prescription patterns. DKSH’s regional scale lets it shift inventory across markets when regulations allow, smoothing these bumps for manufacturers like Roche.
Competition and pricing pressure
Globally, Accu-Chek Guide competes with meter-and-strip systems from Abbott, Ascensia, and several local brands. In some markets, tender systems and insurance formularies determine which strips are reimbursed, while in others, patients buy directly over the counter. That can push manufacturers to lower prices or offer bundled deals with meters. DKSH’s role is to execute these strategies at ground level, working with pharmacies and hospitals to implement promotions and maintain shelf space.
In lower-income markets, price sensitivity is particularly strong. Healthcare budgets and out-of-pocket spending may limit how many strips a patient uses daily. That reality shapes not only Roche’s pricing strategy but also DKSH’s volume expectations. For investors, the upside of accessory products is their repeat nature; the downside is constant pressure on price and reimbursement. Still, diabetes prevalence continues to rise across Asia, which supports long-term demand for blood glucose testing, whether through strips or newer technologies.
Technology shifts: CGM vs strips
Continuous glucose monitoring (CGM) systems are gaining share in developed markets, especially for type 1 diabetics and intensive insulin users. Sensors by companies like Dexcom and Abbott reduce the need for fingerstick tests by providing real-time glucose readings. That trend could, over time, compress test strip volumes in certain segments. However, CGMs are more expensive and require infrastructure for sensor supply and reader devices, which limits penetration in some emerging markets.
DKSH’s Healthcare portfolio includes not only traditional accessories like strips but also more advanced medical devices and diagnostics. As CGM adoption grows, DKSH can pivot toward distributing sensors and related equipment where contracts allow. That diversification helps soften any impact from slower strip growth. For now, fingerstick strips remain the mainstream solution in many Asian countries, and DKSH’s distribution of Accu-Chek Guide boxes continues to be relevant.
Regulation and quality control
Blood glucose test strips are regulated medical devices. Manufacturers must meet performance standards for accuracy and consistency, and distributors must comply with local laws on storage, handling, and traceability. DKSH’s Healthcare division highlights its adherence to Good Distribution Practice (GDP) and other quality frameworks in investor presentations and ESG reporting. Those frameworks cover documentation, temperature control, and complaint handling.
Quality control is particularly sensitive for strips because inaccurate readings can lead to incorrect insulin doses. A meter reading that is off by even 20 percent could tip a patient into hypoglycemia or hyperglycemia. DKSH’s role includes not only correct handling but also managing recalls or field notices when manufacturers identify batch issues. The company’s ability to trace shipments and contact downstream customers quickly is a core competency in such scenarios.
On-the-ground experience
Talk to a diabetes nurse educator in Kuala Lumpur, and they will often mention the importance of reliable strip supply in the same breath as proper injection technique. Patients are trained to recognize their usual range and to respond when readings drift. When a pharmacy temporarily lacks their regular strips, it creates confusion and stress. That human factor rarely shows up in segment charts but drives loyalty and adherence.
For DKSH project managers, that reality translates into meticulously planned replenishment cycles. Shipment schedules must account for public holidays, monsoon disruptions, and infrastructure quirks in each country. You might see pallets of small Accu-Chek boxes moving through large temperature-controlled warehouses, a physical reminder that a seemingly minor accessory product can occupy serious logistics attention. It is not glamorous work, but for people on daily therapy, it is critical.
Investor lens on accessory lines
Many retail investors focus on headline drugs or high-profile medical devices. Accessory products such as Accu-Chek Guide test strips tend to sit in the footnotes. Yet for a services company like DKSH, those footnotes can represent steady, less volatile revenue sources. Healthcare distribution agreements often span multiple years, and consumable products add recurring business within those frameworks.
Shares of DKSH (SIX: DKSH, ISIN CH0012684657) reflect a diversified portfolio that includes Consumer Goods, Performance Materials, and Technology alongside Healthcare. The stock is not a pure play on diabetes or test strips, but this product category illustrates how DKSH monetizes long-term partnerships with global healthcare manufacturers. For US investors, the takeaway is that boring accessories can be part of what makes DKSH’s earnings more predictable than a portfolio of only big-ticket launches.
Accu-Chek Guide test strips at a glance
- Product: Roche Accu-Chek Guide blood glucose test strips (distributed by DKSH in selected Asian markets)
- Manufacturer: Roche Diabetes Care AG (Accu-Chek brand), distribution partner DKSH Holding Ltd.
- Category: Accessories & components (diabetes care consumable)
- Launch: Accu-Chek Guide system introduced globally in the mid-2010s, with subsequent regional rollouts and ongoing availability.
- MSRP / Price: Typically about USD 20–40 per box of 50 to 100 strips in major markets, depending on country, pharmacy, and insurance coverage.
- Availability: Widely available in pharmacies and online in the US and Europe via Roche; distributed by DKSH across selected Asian markets through its Healthcare network.
- Target audience: Adults and children with diabetes who use Accu-Chek Guide meters for fingertip blood glucose monitoring.
- Standout / USP: Spill-resistant dosing area and simple strip handling combined with strong distribution support from partners like DKSH in Asia, turning a small accessory into a reliable, recurring-care element.
This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.
